Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of IMC-S118AI in HLA-A*02:01-Positive Participants With Type 1 Diabetes

NCT07493122 is registered in ClinicalTrials.gov with Immunocore Ltd as lead sponsor.

NCT NCT07493122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07493122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of IMC-S118AI in HLA-A*02:01-Positive Participants With Type 1 Diabetes
Lead sponsor
Immunocore Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
November 30, 2030
Enrollment
154 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes type 1, type 1 diabetes, type 1 diabetes (t1d)